Press Release

Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19

2 October 2019

Jena/Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,459 million in fiscal year 2018/19 (PY: EUR 1,280.9 million), based on preliminary data, and has thereby significantly exceeded the previous forecast of EUR 1,350 to EUR 1,420 million. This corresponds to revenue growth of approximately 13.9% vs. the previous year’s value. After adjustment for currency effects¹, growth amounts to around 11.9 %.

From today’s point of view, the company expects a strong increase in operating earnings² (EBIT) and anticipates to significantly exceed the previous forecast of an EBIT margin³ between 15.0% to 17.5% (PY: 15.4%) as well as current market expectations estimated at around 18.5%.

Full results for business year 2018/19 will be provided on Dec 6, 2019.

As already reported after nine months 2018/19, management expects no further sustainable increase in EBIT margin in fiscal year 2019/20, partly due to planned strategic investments in research and development.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Share this article

¹
Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
²
Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation).
³
Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).